Jan 14, 2020: The U.S. FDA is alerting the public that results from a clinical trial assessing safety shows possible increased risk of cancer with the weight management medicine Belviq, Belviq XR (lorcaserin).
The cause of the cancer is uncertain, and cannot concluded that lorcaserin contributes to the cancer risk. Clinical trial results evaluation will communicate the final conclusions and recommendations when completed our review.
Health care professionals should believe if the benefits of taking lorcaserin are likely to exceed the potential risks when deciding whether to prescribe or continue patients on lorcaserin.
Lorcaserin is a prescription medicine approved by FDA in 2012 for use with a reduced-calorie diet and increased physical activity in order to help weight loss in adults who are stout or are overweight and have weight-related medical problems.
Lorcaserin increases feelings of fullness so that less food is eaten, available as a tablet (Belviq) and an extended-release tablet (Belviq XR). https://www.fda.gov/drugs/drug-safety-and-availability/safety-clinical-trial-shows-possible-increased-risk-cancer-weight-loss-medicine-belviq-belviq-xr